Relative Serum Antiplasmin Levels in Normal and Hemophilic Dogs Treated with Choline

Summary

Peroral administration of choline in relatively high dosage (300 or 600 mg choline dihydrogen citrate per 17-20 lb body weight, 4 times daily) caused no significant change in serum antiplasmin activity of either normal or factor VIII-deficient beagle dogs. Also, no alteration in antiplasmin level was found to be associated with the hemophilic state.

Canine serum antiplasmins are stable at low temperatures. Like human antiplasmins, they appear to have two major components which differ conspicuously in stability at 60° C.

Other data presented in this paper show that crude plasmin readily obtained from human serum euglobulins provides an enzyme preparation suitable for screening antiplasmin levels of sera by the caseinolytic method.

• References

• 1 Astrup T. Fibrinolytic mechanisms in man and animals. In: Dynamics of Thrombus Formation and Dissolution. Johnson S. A, Guest M. M. Eds. J. B. Lippincott Co; Philadelphia: 1969: 275-305.
• 2 Booth P. B, MacGregor A. Comparisons of fibrinolysis and blood coagulation in Melanesians and Caucasians. Brit. J. Haemat IS: 779 1967;
• 3 Boudreaux H. B, Frampton V. L. A peanut factor for haemostasis in haemophilia. Nature (Lond) 755: 469 1960;
• 4 Brody J. I, Mobarak M, Lau P, Beizer L. H. Fibrinolysis studies in hemophilia. Arch, intern. Med 118: 241 1966;
• 5 Brown W. F. II. Choline-induced inhibition of fibrinolysis in normal and hemophilic dogs (thrombelastography) Ph. D. Dissertation. Louisiana State University; 1969
• 6 Brown W. F, Boudreaux H. B, Jackson B, Myers R. B. Choline-induced inhibition of fibrinolysis (thrombelastography) in normal and hemophilic dogs. Manuscript submitted in May, 1971, to editors of Thrombos. Diathes. haemorrh. (Stuttg.).
• 7 Gelander E, Gelander D. R. Comparison of in vivo effects on components of the canine fibrinolytic enzyme system of AMCHA fed at varying dose levels. Thrombos. Diathes. haemorrh. (Stuttg) 20: 574 1968;
• 8 van Creveld S, Mochtar I. A, Koppe J. G. Haemophilia and therapy with peanuts, II. Ann. paediat. (Basel) 202: 1 1964;
• 9 Frampton V. L, Lee L. S, Morris N. J, Boudreaux H. B. Influence of peanut extract on bleeding time. Thrombos. Diathes. haemorrh. (Stuttg) 16: 265 1966;
• 10 Gans H, Subramanian V, John S, Castaneda A. R, Lillehei G. W. Theoretical and practical (clinical) considerations concerning proteolytic enzymes and their inhibitors with particular reference to changes in the plasminogen - plasmin system observed during assisted circulation in man. Ann. N. Y. Acad. Sei. 146 (2) : 721 1968;
• 11 Gans H, Tan B. H. Alpha-1 antitrypsin, an inhibitor for thrombin and plasmin. Clin. chim. Acta 17: 111 1967;
• 12 Guest M. M, Daly B. M, Ware A. G, Seegers W. H. A study of antifibrinolysis activity in the plasmas of various animal species. J. clin. Invest 27: 785 1948;
• 13 Hawkey G. M, Stafford J. L. A standard clot method for the assay of plasminogen activators, anti-activators, and plasmin. J. clin. Path 17: 175 1964;
• 14 Jackson B, Owen W, Boudreaux H. B. Pharmacological and chemical characteristics of peanut extracts effective in hemostasis. Thrombos. Diathes. haemorrh. (Stuttg) 16: 257 1966;
• 15 Johnson A. J, Kline D. L, Alkjaersig N. Assay methods and standard preparations for plasmin, plasminogen and urokinase in purified systems. 1967-1968. Thrombos. Diathes. haemorrh. (Stuttg) 21: 259 1969;
• 16 Lewis J. H, Ferguson J. H. Studies on a proteolytic enzyme system of the blood. I. Inhibition of fibrinolysin. J. clin. Invest 29: 486 1950;
• 17 Moriau M, de Vries S. I, Dik H. J. Les inhibiteurs de la fibrinolyse et la dosage de l’activité antiplasminique physiologique et pathologique. Thrombos. Diathes. haemorrh. (Stuttg) 10: 355 1964;
• 18 Naeye R. L. Thrombotic disorders with increased levels of antiplasmin and antiplasminogen. New Engl. J. Med 265: 867 1961;
• 19 Niewiarowski S, Wolosowicz N. The in-vivo effect of E-aminocaproic acid (EACA) on human plasma fibrinolytic system. Thrombos. Diathes. haemorrh. (Stuttg) 15: 401 1966;
• 20 Nilsson I. M, Krook H, Sternby N-H, Soderberg E, Söderström N. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with high content of an inhibitor of the fibrinolytic system. Acta med. scand 169: 323 1961;
• 21 Norman P. S. Studies of the plasmin system. I. Measurement of human and animal plasminogen. Measurement of an activator in human serum. J. exp. Med 106: 423 1957;
• 22 Norman P. S. Studies of the plasmin system. II. Inhibition of plasmin by serum or plasma. J. exp. Med 108: 53 1958;
• 23 Norman P. S, Hill B. M. Studies of the plasmin system. III. Physical properties of the two plasmin inhibitors in plasma. J. exp. Med 108: 639 1958;
• 24 Sandberg H, Tsitouris G, de Leon A. G, Bellet S. Studies of inhibition of the plasmin - plasminogen fibrinolytic enzyme system in patients with myocardial infarction. Amer. J. Cardiol 05: 666 1960;
• 25 Shamash Y, Rimon A. The plasma inhibitors of plasmin. I. A method for their estimation. Thrombos. Diathes. haemorrh. (Stuttg) 12: 119 1964;
• 26 Sherry S, Alkjaersig N. Biochemical, experimental, and clinical studies of proteolytic enzymes: With particular reference to the fibrinolytic enzyme of human plasma. Ann. N. Y. Acad. Sei 68 (01) 52 1957;
• 27 Sherry S, Alkjaersig N. Studies on the fibrinolytic system of human plasma. Thrombos. Diathes. haemorrh. (Stuttg) 01: 264 1957;
• 28 Sherry S, Lindemeyer R. I, Fletcher A. P, Alkjaersig N. Studies on enhanced fibrinolytic activity in man. J. clin. Invest 38: 810 1959;